Ionis Pharmaceuticals Inc (IONS)
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a potential first-in-class medicine for chronic hepatitis B
📈 **POSITIVE** • High confidence analysis (94%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business